about
Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy.Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle?The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case reportLiver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage.Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3.Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea.Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study."Non alcoholic fatty liver disease and eNOS dysfunction in humans"Antiviral therapy: why does it fail in HCV-related chronic hepatitis?Management of adults with paediatric-onset chronic liver disease: strategic issues for transition care.Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis.Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma.Pharmacotherapy of alcoholic liver disease in clinical practice.Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project).Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction.HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells.Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.Timed regulation of P-element-induced wimpy testis-interacting RNA expression during rat liver regeneration.Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients.Steatosis as a co-factor in chronic liver diseases.Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.Treatment of patients with HCV infection with or without liver biopsy.A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas.Hepatitis C virus RNA in serum and liver histology in asymptomatic anti-HCV positive subjects.Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease.Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee.Clinical management of HCV carriers with normal aminotransferase levels.Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis.
P50
Q31032339-7A3DB077-2279-482E-8F4A-6D1F5428E5E5Q33350030-1DDC0469-6D51-4909-B007-361D7C7909D4Q33412844-80498682-DE5B-4476-BD1B-CDB8623707D1Q33751826-41DD19AB-FD8B-4F79-B2F7-3036C2B9DE6CQ33937093-66F31D4A-5594-4602-9760-236C25FBF3FEQ34467208-A0E15370-8C4E-4C06-8CD9-87B5DF15ED5DQ35044215-602BD0F9-72A6-48AD-ACE4-626879A8FB62Q35095916-92672167-EBDE-405A-8881-9FF39B2FF6CDQ35941510-A11BE11A-9536-4BDE-8520-92253442EC36Q36298719-7D19942C-FA86-470A-92B8-516D5411B680Q37879193-444F8A70-C686-4239-ADA3-1E3B71FE2C9CQ38169837-3866B103-00A6-4BF0-8DFF-5ECA10A1AC77Q38629161-F6F0C33A-2D8C-45A7-B5D0-D8625937BB17Q38676280-6308FCC4-80CC-4768-A163-716062E21390Q38681092-23900F27-293A-4547-B8EF-930D9865D0CFQ39240225-BCC487A1-9286-471A-A7C9-62D7A0372F9FQ40121053-E0029031-2193-4D40-BAA8-9ACB72591944Q40165178-2B7DE46A-753B-47F9-B831-6AFB612521F4Q40335094-67EE51A4-BA37-4F52-A004-5C351B33279BQ40343764-C82ED497-ACA8-4749-AC5C-FB9186018652Q40446903-B18D8DF8-D414-45C8-A486-A8256C62227CQ41342858-5626E806-7D35-4568-8932-61FCCB54E730Q41487313-2A1F3AFA-3ABB-4A1E-94DF-B8FAA7CB1DD8Q41918943-13F0B74F-1035-43C5-A43B-BE9E2A5D1CD0Q42460664-5DEFC3D3-305B-460A-8793-DD500341D2AFQ42538067-3FD92029-9736-4141-B9C5-C145D22FD36FQ42870806-214F5658-6D96-4738-843A-2CD0216D322DQ42980538-DDB0468D-5E30-4949-860D-A89D57ADBD15Q42988394-268C15A4-9D77-4814-9847-408E55578416Q42992074-6B50C48A-3017-4774-8DA9-3FDA50567C6EQ42993387-88C3F62D-3167-4F6B-9E01-3C814D74C7F6Q43036224-DD3D78BD-4C47-4F24-98BC-1F43F8C446A6Q43036320-282D9054-5C73-4BED-9A30-597A28FAE94BQ43036848-7F2F149A-7117-41DC-9FC5-9ACE3B442CE5Q43036983-B5DB1DEB-B36D-47B3-AD81-239CF357E1C3Q43040750-ECD47970-21FF-45A8-8CB5-010E84E9716BQ43155716-DBBD762F-AB86-427F-A7F7-0A063D930265Q44151669-EC8A7C5A-ED54-4F1D-8FCA-6994FDC1E8F7Q44195299-E4C8323A-A670-4BB0-9CD8-E3D4516FE416Q44211166-745974F0-82D8-4314-953D-70A98B3BC301
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marcello Persico
@ast
Marcello Persico
@en
Marcello Persico
@es
Marcello Persico
@nl
Marcello Persico
@sl
type
label
Marcello Persico
@ast
Marcello Persico
@en
Marcello Persico
@es
Marcello Persico
@nl
Marcello Persico
@sl
prefLabel
Marcello Persico
@ast
Marcello Persico
@en
Marcello Persico
@es
Marcello Persico
@nl
Marcello Persico
@sl
P106
P1153
7101829724
P21
P31
P496
0000-0002-1399-6498